{Reference Type}: Journal Article
{Title}: Phase II study in children and adults under 40 years with newly diagnosed Langerhans cell histiocytosis: protocol for an LCH-19-MSMFB clinical trial in Japan.
{Author}: Ono R;Sakamoto K;Kudo K;Sato A;Kudo K;Fujino H;Kawahara Y;Hashimoto H;Doi T;Yanagisawa R;Kawamata T;Miyazaki O;Nakazawa A;Ota Y;Kanegane H;Nakazawa Y;Horibe K;Saito AM;Manabe A;Usuki K;Kiyoi H;Morimoto A;Tojo A;Shioda Y;
{Journal}: BMJ Open
{Volume}: 14
{Issue}: 6
{Year}: 2024 Jun 23
{Factor}: 3.006
{DOI}: 10.1136/bmjopen-2024-084159
{Abstract}: <B>BACKGROUND: </B>Although the prognosis of Langerhans cell histiocytosis (LCH) is excellent, the high recurrence rate and permanent consequences, such as central diabetes insipidus and LCH-associated neurodegenerative diseases, remain to be resolved. Based on previous reports that patients with high-risk multisystem LCH show elevated levels of inflammatory molecules, we hypothesised that dexamethasone would more effectively suppress LCH-associated inflammation, especially in the central nervous system (CNS). We further hypothesised that intrathecal chemotherapy would effectively reduce CNS complications. We administer zoledronate to patients with multifocal bone LCH based on an efficacy report from a small case series.<BR><B>METHODS: </B>This phase II study (labelled the LCH-19-MSMFB study) is designed to evaluate the significance of introducing dexamethasone and intrathecal chemotherapy for multisystem disease and zoledronate for multifocal bone disease in previously untreated, newly diagnosed children, adolescents (under 20 years) and adults under 40 years. The primary endpoint is the 3-year event-free survival rate by risk group of under 20 years and the 3-year event-free survival rate of 20 years and over.<BR><B>BACKGROUND: </B>This study was approved by the Central Review Board of the National Hospital Organisation Nagoya Medical Centre (Nagoya, Japan) on 21 January 2022 and was registered in the Japan Registry of Clinical Trials (https://jrct.niph.go.jp/en-latest-detail/jRCTs041210027). Written informed consent will be obtained from all patients and/or their guardians.<BR><B>BACKGROUND: </B>jRCTs041210027.